Pancreatic Cancer Precision Medicine Global Market Report 2025

The pancreatic cancer precision medicine market size has grown rapidly in recent years. It will grow from $0.49 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth during the historic period can be attributed to several factors, including the rising incidence of pancreatic cancer, advancements in the understanding of tumor heterogeneity, increased investment in oncology research, greater availability of biomarker-driven therapies, improved diagnostic tools for early detection, and a growing adoption of personalized treatment approaches.

The pancreatic cancer precision medicine market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 17.9%. The growth during the forecast period can be attributed to several factors, including increasing investments in personalized oncology research, greater availability of biomarker-based diagnostic tests, rising adoption of targeted therapies, a growing pipeline of clinical trials for precision treatments, supportive regulatory initiatives for personalized medicine, and expanding collaborations between biotech companies and research institutions. Key trends in the forecast period include advancements in liquid biopsy technologies, the development of personalized immunotherapies, the adoption of AI-driven predictive analytics, the emergence of new biomarker discoveries, the integration of multi-omics approaches for more detailed tumor profiling, and the rise of targeted combination therapies.

The growing incidence of pancreatic cancer is anticipated to drive the expansion of the pancreatic cancer precision medicine market. Pancreatic cancer, which begins in the pancreas - an organ crucial for digestion and blood sugar regulation - has seen a rise in cases due to factors such as an aging population and the increasing prevalence of risk factors such as obesity, diabetes, and smoking. Precision medicine for pancreatic cancer improves treatment outcomes by providing personalized treatment plans based on genetic and molecular data. This approach enhances treatment effectiveness and minimizes side effects, making it an essential tool for more efficient cancer management. For example, in February 2025, Cancer Australia reported that there were 4,641 new cases of pancreatic cancer in 2024, with 2,414 in males and 2,227 in females, marking an increase from 3,968 cases in 2023. As such, the growing incidence of pancreatic cancer is contributing to the growth of the precision medicine market for this disease.

Leading companies in the pancreatic cancer precision medicine market are increasingly focusing on developing advanced technologies, such as precision medical tools, to enhance early detection, enable accurate tumor profiling, and optimize personalized treatment strategies for better patient outcomes. Precision medical tools are specialized devices that assist in diagnosing and treating diseases based on an individual’s unique biology. For instance, in January 2024, Cedars-Sinai, a U.S.-based healthcare organization, launched the molecular twin precision oncology platform. This tool aims to more accurately predict pancreatic cancer survival by identifying key biomarkers. The platform has strong potential for guiding treatment decisions, even in areas with limited resources, by using blood and tissue samples from 74 pancreatic ductal adenocarcinoma patients to provide a more precise and accessible approach to precision oncology.

In September 2022, Oncodesign Precision Medicine (OPM), a biotechnology firm based in France, entered into a collaboration with Servier Laboratories to identify and validate new therapeutic targets in pancreatic ductal adenocarcinoma (PDAC). This collaboration seeks to accelerate the development of precision medicine for cancer treatment by combining OPM’s expertise in biomarkers and therapeutic solutions with Servier’s oncology research and drug development capabilities. Servier Laboratories is a French pharmaceutical company specializing in treatments for oncology and immuno-inflammatory diseases.

Major players in the pancreatic cancer precision medicine market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, Eli Lilly and Company, Amgen Inc, Teva Pharmaceutical Industries Ltd, Genentech Inc., Illumina Inc., Ipsen Pharma, Guardant Health, FOUNDATION MEDICINE INC., Oncolytics Biotech Inc., Celgene Corporation, Erytech Pharma, PharmaCyte Biotech Inc.

North America was the largest region in the pancreatic cancer precision medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pancreatic cancer precision medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pancreatic cancer precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pancreatic cancer precision medicine is a specialized treatment approach that tailors care to individual pancreatic cancer patients. It uses the patient’s genetic and molecular information, both from their body and their cancer, to develop a personalized treatment plan. This approach improves patient outcomes by customizing treatment, reducing unnecessary interventions, and increasing the chances of successful outcomes.

The primary therapeutic strategies in pancreatic cancer precision medicine include targeted therapy, immunotherapy, chemotherapy-precision combinations, and others. Targeted therapy involves drugs specifically designed to act on genetic mutations, proteins, or other molecules that contribute to the growth and spread of cancer cells. A variety of diagnostic technologies support these treatments, such as genomic testing, molecular diagnostics, liquid biopsy, and biomarker-based companion diagnostics. These technologies and therapies are applied in settings such as hospitals, specialty clinics, academic and research institutes, and diagnostic centers.

The pancreatic cancer precision medicine market research report is one of a series of new reports that provides pancreatic cancer precision medicine market statistics, including the pancreatic cancer precision medicine industry global market size, regional shares, competitors with the pancreatic cancer precision medicine market share, detailed pancreatic cancer precision medicine market segments, market trends, and opportunities, and any further data you may need to thrive in the pancreatic cancer precision medicine industry. This pancreatic cancer precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pancreatic cancer precision medicine market includes revenues earned by entities by providing services such as personalized treatment planning, tumour molecular profiling, precision imaging and diagnostics, and targeted therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic cancer precision medicine market consists of sales of genetic and biomarker testing kits, immunotherapy drugs, and personalized cancer vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.